Get all premium features to the best stock analysis tool

Cellgenic is expanding local representation and commercial support in Brazil, one of Latin America's larger healthcare and aesthetic-medicine markets. ISSCA continues to hold physician-education events in São Paulo.

Peru becomes the newest addition to Cellgenic's Latin American commercial network - one of three coordinated market initiatives across the region, subject to applicable local regulatory requirements. MIAMI, FL / ACCESS Newswire / September 1, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced the commencement of Cellgenic commercial activity in Peru through the establishment of local commercial arrangements, including exclusive representation arrangements in permitted channels.

A second cellular-technology launch in close succession broadens Cellgenic's portfolio into Latin America, the Middle East, Europe, and Southeast Asia, demonstrating a repeatable product-development motion. MIAMI, FL / ACCESS Newswire / August 27, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced the introduction, through its Cellgenic division, of a multilineage-differentiating stress-enduring (MUSE) cell product line for selected international markets - including Latin America, the Middle East, Europe, and Southeast Asia - subject to applicable local regulatory requirements.

New Website Serves as a Central Source for Investor Information and Timely Disclosure; Investor Inquiries Directed to [email protected] MIAMI, FL / ACCESS Newswire / August 26, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced that it has acquired the domain name RMTG.com , and launched a new investor-focused corporate website at that address. The site is intended to serve as a central, easily accessible destination for the Company's investor communications, corporate information, and public disclosures.

New NK cell platform extends RMTG's cellular-technology portfolio into immunology-adjacent applications, with an initial commercial focus on Latin America and Southeast Asia. MIAMI, FL / ACCESS Newswire / August 24, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, announces the launch, through its Cellgenic division, of a Natural Killer (NK) cell product line for permitted markets outside the United States, with an initial commercial focus on Latin America and Southeast Asia.

Continued Acceleration in 2026 With Record Revenue, Expanding Margins, Growth in Operating Profit, and Accelerating Training and Product Supply Sales MIAMI, FL / ACCESS Newswire / August 20, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced its financial results for the second quarter of 2026 (Q2 2026), for the period ended June 30, 2026,as reported in the Company's Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on August 19, 2026. The results reflect record revenue and gross profit growth for the Company, driven by rapid expansion in physician training and product supply sales, a growing base of recurring Affiliate membership revenue, and a global clinic network spanning more than 30 countries.

Company Announces Date, Time and Connection Details for Its Inaugural Investor Call Following a Strong First Half of 2026 MIAMI, FL / ACCESS Newswire / August 19, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced the connection details for its first-ever investor call, during which management will present prepared remarks responding to questions submitted by shareholders. The call reflects the Company's strong performance through the first half of 2026 and management's commitment to increased transparency and engagement with its shareholders.